别孕烯醇酮-治疗产后抑郁的新药  

Brexanolone:a new drug for postpartum depression

作　　者：张金桂 王超[1] 万培玲[1] 杨宇婷 Zhang Jingui;Wang Chao;Wan Peiling;Yang Yuting(Department of Pharmacy,the Peoples Hospital of Hainan,Haihou,Hainan 570311,China)

机构地区：[1]海南省人民医院药学部,海口570311

出　　处：《中国基层医药》2019年第24期3070-3072,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：别孕烯醇酮又称3α、5α-四氢孕酮,是孕酮的一种代谢产物,也是重要的神经活性甾体,具有广泛的生物学活性.让人振奋的是2019年美国食品药品监督管理局(FDA)已批准其治疗产后抑郁症,也是目前唯一一种获得产后抑郁适应证的药物,预期将于2019年6月底正式进入市场.本文将对其药理作用研究进展做一综述.Brexanolone,also known as 3a,5a-tetrahydroprogesterone ,is a metabolite of progesterone and an important neuroactive steroid with a wide range of biological activities.Recently,the most exciting thing is that 2019 year the FDA has approved its treatment of postpartum depression ,which is also the only drug to obtain indications for postpartum depression.It is expected to officially enter the market by the end of June 2019 year.This article reviews the research progress of its pharmacological action.

关 键 词：抑郁症 产后 孕酮 抗抑郁药 药理作用 别孕烯醇酮 

分 类 号：R74[医药卫生—神经病学与精神病学]